报价延迟最少15分钟:2026/01/10 05:07 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8198 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-24.24/-187.84
|
|
企业价值
8.22M
|
| 资产负债 |
|
每股账面净值
0.72
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
838.14K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. |
